ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
10/06/2026
Voltar para busca
Dado oficial do USPTO
E-THERAPEUTICS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
E-THERAPEUTICS
ST13
US500000097497975Classe
5, 9, 40, 42
Pedido
97497975
Registro
7567980
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
31
Atualização mais recente
11/06/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 9, 40, 42
Data de depósito
11/07/2022
Data de registro
19/11/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
19/11/2024
Última transação
11/06/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
4
Tipo de titular
84
Localização do titular
LONDON, GB
Examinador
WOOD, CAROLINE
Unidade examinadora
M10
Localização atual
INTENT TO USE SECTION
Titulares e representantes
Titulares
TANGRAM THERAPEUTICS PLC
E-THERAPEUTICS PLC
Representantes
Anna King BANNER & WITCOFF, LTD.
Classificação técnica
Classes Nice
Classe 5Classe 9Classe 40Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical and medical preparations for use in targeting genes and silencing or inhibiting gene expression; RNAi-based medicines and pharmaceuticals for use in targeting genes and blockingsilencinginhibiting gene expressionfor use in targeting mRNA and triggering its degradation; short interfering RNA (siRNA) medicines and pharmaceuticals for use in targeting genes and blockingsilencinginhibiting gene expressionfor use in targeting mRNA and triggering its degradation; nucleic acid-based drugs (NABDs) for blockingsilencing or inhibiting gene expression; pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation; none of the aforementioned goods forrelated toT-cells or T-cell receptors
Classe 9
Downloadable and recorded computer software for modelling genetic sequences and gene-disease associationsfor identifying and ranking potential gene targetsfor generating pharmaceutical and medical preparationsfor use in the fields of pharmaceuticalsmedicines and drug discovery; downloadable computer software using artificial intelligence for machine learning for use in the field of pharmaceuticalsmedicines and drug discovery; recorded computer software using artificial intelligence for machine learning for use in the field of pharmaceuticalsmedicines and drug discovery; downloadable databases in the field of pharmaceuticalsmedicines and drug discovery; electronic databases recorded on computer mediafor use in the field of pharmaceuticalsmedicines and drug discovery; downloadable and recorded computer platform software for modelling genetic sequences and gene-disease associationsfor identifying and ranking potential gene targetsfor generating pharmaceutical and medical preparations; downloadable and recorded computer software platforms for modelling genetic sequences and gene-disease associationsfor identifying and ranking potential gene targetsfor generating pharmaceutical and medical preparationsfor use in the fields of pharmaceuticalsmedicines and drug discovery; none of the aforementioned goods forrelated toT-cells or T-cell receptors
Classe 40
Custom manufacture of pharmaceutical and medical preparations; custom manufacture of pharmaceutical and medical preparations for use in targeting genes and blockingsilencing or inhibiting gene expression; custom manufacture of RNAi-based pharmaceuticals and medicines; custom manufacture of short interfering RNA (siRNA) medicines; custom manufacture of nucleic acid-based drugs (NABDs) for blockingsilencing or inhibiting gene expression; custom manufacture of pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation; provision of informationadvice and consultancy services relating to all of the aforesaid; none of the aforementioned services forrelated toT-cells or T-cell receptors
Classe 42
Scientific research and development; pharmaceutical research and development services; scientific research and development in the field of targeting genes and blockingsilencing or inhibiting gene expression; scientificpharmaceutical and medical research and development services relating to RNAi-based pharmaceuticals and medicines; scientificpharmaceutical and medical research and development services relating to pharmaceutical and medical preparations for use in targeting genes and blockingsilencing or inhibiting gene expression; scientificpharmaceutical and medical research and development services relating to short interfering RNA (siRNA) medicinesnucleic acid-based drugs (NABDs) for blocking gene expressionnucleic acid-based drugs (NABDs) for blockingsilencing or inhibiting gene expressionandpharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; drug discovery services; drug discovery services relating to RNAi-based pharmaceuticals and medicines; drug discovery services relating to pharmaceutical and medical preparations for use in targeting genes and blockingsilencing or inhibiting gene expression; drug discovery services relating to short interfering RNA (siRNA) medicinesnucleic acid-based drugs (NABDs) for blockingsilencing or inhibiting gene expressionpharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; human genetic research; scientific and technical data analysis in the field of pharmaceuticalsmedicines and drug discovery; scientific and technical data analysis in relation to pharmaceuticals and medicines; scientific and technical data analysis in relation to RNAi-based medicines; scientific and technical data analysis in relation to pharmaceutical and medical preparations for use in targeting genes and blockingsilencing or inhibiting gene expression; scientific and technical data analysis in relation to short interfering RNA (siRNA) medicinesnucleic acid-based drugs (NABDs) for blockingsilencing or inhibiting gene expressionpharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; designdevelopmentcreation and maintenance of computer platforms and computer software; designdevelopmentcreation and maintenance of computational computer software platforms; designdevelopmentcreation and maintenance of computer software platforms and computer software for use in the field of pharmaceuticalsmedicines and drug discovery; Platform as a Service (PaaS) featuring computer software platforms for modelling genetic sequences and gene-disease associationsfor identifying and ranking potential gene targetsfor generating pharmaceutical and medical preparationsfor use in the field of pharmaceuticalsmedicines and drug discovery; Platform as a Service (PaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for use in the field of pharmaceuticalsmedicines and drug discoveryfor modelling genetic sequences and gene-disease associationsfor identifying and ranking potential gene targetsfor generating pharmaceutical and medical preparations; Platform as a Service (PaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for use in the field of pharmaceuticalsmedicinesdrug discoveryfor modelling genetic sequences and gene-disease associationsfor identifying and ranking potential gene targetsfor generating RNAi-based medicines and pharmaceuticalsshort interfering RNA (siRNA) medicinesnucleic acid-based drugs (NABDs) for blockingsilencing or inhibiting gene expressionpharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; design and development of computer-simulated models; design of computer-simulated models for use in the field of pharmaceuticalsmedicines and drug discovery; providing temporary use of online non-downloadable computer software for modelling genetic sequences and gene-disease associationsfor identifying and ranking potential gene targetsfor generating pharmaceutical and medical preparationsfor use in the field of pharmaceuticalsmedicines and drug discovery; providing temporary use of online non-downloadable computer software for modelling genetic sequences and gene-disease associationsfor identifying and ranking potential gene targetsfor generating pharmaceutical and medical preparationsfor use in the field of pharmaceuticalsmedicines and drug discovery; Software as a Service (SaaS); Software as a Service (SaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for use in the field of pharmaceuticalsmedicines and drug discoveryfor modelling genetic sequences and gene-disease associationsfor identifying and ranking potential gene targetsgenerating pharmaceutical and medical preparations; Software as a Service (SaaS) services featuring computer software platforms using artificial intelligence and machine learning for use in the field of pharmaceuticalsmedicines and drug discoveryfor modelling genetic sequences and gene-disease associationsfor identifying and ranking potential gene targetsfor generating RNAi-based medicines and pharmaceuticalsnucleic acid-based drugs (NABDs) for blockingsilencing or inhibiting gene expressionpharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; provision of informationadvice and consultancy services relating to all of the aforesaid; none of the aforementioned services forrelated toT-cells or T-cell receptors
Publicações
Histórico de despachos e eventos da marca no USPTO.
31 publicações encontradas
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
19/11/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
19/11/2024
DP1B
1(B) BASIS DELETED; PROCEED TO REGISTRATION
15/10/2024
IUCN
NOTICE OF ALLOWANCE CANCELLED
15/10/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
15/10/2024
D1BR
TEAS DELETE 1(B) BASIS RECEIVED
26/09/2024
EPPA
TEAS POST PUBLICATION AMENDMENT RECEIVED
12/09/2024
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
16/04/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/03/2024
PUBO
PUBLISHED FOR OPPOSITION
20/02/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
31/01/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
31/01/2024
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
18/01/2024
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
12/01/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/01/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
05/01/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
05/01/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
05/01/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
05/01/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
30/11/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
30/11/2023
ALIE
ASSIGNED TO LIE
30/11/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
26/06/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
27/04/2023
GNRT
NON-FINAL ACTION E-MAILED
27/04/2023
CNRT
NON-FINAL ACTION WRITTEN
27/04/2023
DOCK
ASSIGNED TO EXAMINER
25/04/2023
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
19/04/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
29/07/2022
NWAP
NEW APPLICATION ENTERED
14/07/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace E-THERAPEUTICS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.